Table 2.
Influenza vaccine characteristics by vaccine brand in the 2021–2022 season—vaccines licensed and marketed in Europe.
| Vaccine brand | Manufacturer | Valency | Type | Adjuvant | Culture | HA antigen content | Approved age indication | Countries (regions) where the vaccine brand was observed in the DRIVE dataset, by age group | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 6 months−17 years | 18–64 years | ≥65 years | ||||||||
| Afluria Tetraa | Seqirus | 4 | I | Non-Adj | Egg | SD | ≥18 years | – | – | – |
| Chiroflu | Seqirus | 3 | I | Non-Adj | Egg | SD | ≥6 months | – | – | – |
| Eflueldaab | Sanofi | 4 | I | Non-Adj | Egg | HD | ≥60 years | n/a | AU | IT, SP (CT), AU, FR |
| Fluadb | Seqirus | 3 | I | Adj | Egg | SD | ≥65 years | n/a | n/a | SP (V, M, CL), IT |
| Fluad Tetraab | Seqirus | 4 | I | Adj | Egg | SD | ≥65 years | n/a | n/a | IT, SP (CT, CL), AU |
| Fluarix Tetrab | GSK | 4 | I | Non-Adj | Egg | SD | ≥6 months | IT, AU | IT, AU | IT, AU |
| Flucelvax Tetrab | Seqirus | 4 | I | Non-Adj | Cell (M) | SD | ≥2 years | – | IT, AU, SP (V) | IT, AU, SP (V) |
| Fluenz Tetrab | AstraZeneca | 4 | LA | Non-Adj | Egg | SD | 2–17 years | IT, AU, FI | n/a | n/a |
| Influvac | Abbott | 3 | I | Non-Adj | Egg | SD | ≥6 months | – | – | – |
| Influvac Tetrab | Abbott | 4 | I | Non-Adj | Egg | SD | ≥6 months | AU, SP (V) | AU, SP (V, CT), RO, FR | AU, SP (V, CT), ICE, FR |
| Supemteka | Sanofi | 4 | R | Non-Adj | Cell (In) | SD | ≥18 years | – | – | – |
| Vaxigrip Tetrab | Sanofi | 4 | I | Non-Adj | Egg | SD | ≥6 months | ICE, IT, AU, FI, RO | ICE, IT, AU, FR, RO, SP (CT, M, CL) | ICE, IT, AU, FR, SP (CT), FI |
aNewly available in the EU/EEA/UK in the 2021–2022 season.
bInfluenza vaccines reported in the DRIVE database for the 2021–2022 season.
Adj, adjuvanted; AU, Austria; FI, Finland; FR, France; HD, high dose; I, inactivated; ICE, Iceland; In, insect cells; IT, Italy; LA, live attenuated; M, mammalian cells; Non-Adj, non-adjuvanted; R, recombinant; RO, Romania; SD, standard dose; SP, Spain (CT, Catalonia; CL, Castilla y León; M, Madrid; V, Valencia).